Alnylam’s lumasiran is latest RNAi therapeutic to hit pivotal study goal

Lumasiran’s success in a pivotal study to treat a form of hyperoxaluria represents another step toward Alnylam meeting its updated goal of having four approved medicines by the end of 2020 -- all since the summer of 2018.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Tuesday that RNAi therapeutic lumasiran met

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE